1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Published ADAPT Results Further Support Medtronic’s Highly Anticipated 780G

 
• By Barnaby Pickering

Ohad Cohen, director of medical affairs for Medtronic Diabetes EMEA, talked to Medtech Insight about the published results from the ADAPT trial, which showed that Medtronic’s advanced hybrid closed loop insulin delivery technology provides better glycemic control than standard therapies.

Ohad Cohen likened Medtronic's 780G to a Ferrari compared to other treatments, which he described as a donkey. • Source: Shutterstock

Medtronic has continued to publish more good news about the device it is banking on to save its fortunes in the diabetes management devices market.

What Is The 780G?

When combined with a compatible glucose monitor, Medtronic’s 780G pump creates a hybrid closed-loop system – the closest approximation of an “artificial pancreas” currently available to people with diabetes.

The glucose monitor measures blood glucose levels and the pump delivers insulin in response to current readings. Additionally, predictive algorithms estimate future blood glucose levels, ensuring more regular glycemic control.

For patients, this creates a much more hands-off experience, where manual involvement is typically only needed before a carb or sugar heavy meal.

The 780G earned a CE mark in 2020 and the company is seeking US Food and Drug Administration approval for the pairing of the 780G pump and its Guardian 4 continuous glucose monitor. (Also see "ATTD 2022: Mic Drop Moment As Medtronic Presents 780G Data Proving Closed Loop Ability" - Medtech Insight, 28 April, 2022.) 

Medtronic has been struggling to compete with Abbott and DexCom over the past three years because it does...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Roche Eyes 2026 FDA Nod After CE Mark For pTau181 Test To Boost Global Alzheimer’s Diagnosis

 
• By Shubham Singh

The Elecsys pTau181 test, which requires only a blood sample, provides a less invasive alternative to cerebral spinal fluid procedures. A negative result could rule out Alzheimer’s and help patients avoid further testing with CSF or PET scans.

HistoSonics Sells Majority Stake To Investor Syndicate In Deal Valued At $2.25Bn

 
• By Marion Webb

HistoSonics’ CEO Michael Blue describes the deal as a win-win for all stakeholders and plans to use the money to expand clinical indications, as well as the global reach, for its Edison system.

Ultromics Wins $55M, The Key To Success: Diagnosing Diseases With Available Treatment

 
• By Natasha Barrow

Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.

CorTec Begins First Human Trial Of Wireless Brain Implant For Stroke Rehab

 
• By Marion Webb

Germany’s CorTec has implanted its wireless brain-computer interface in a stroke patient, launching a trial to test safety and whether brain stimulation during physical therapy can help restore movement where traditional rehab has failed.

More from R&D

CorTec Begins First Human Trial Of Wireless Brain Implant For Stroke Rehab

 
• By Marion Webb

Germany’s CorTec has implanted its wireless brain-computer interface in a stroke patient, launching a trial to test safety and whether brain stimulation during physical therapy can help restore movement where traditional rehab has failed.

NIH-Backed Scanner Opens New Frontier For Understanding The Human Brain

 
• By Brian Bossetta

A new MRI scanner developed by a team of scientists working with the National Institutes of Health marks a milestone in understanding the complexities of the human brain. Andrea Beckel-Mitchener with the NIH Brain Initiative discusses the significance of this potentially game-changing device.

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 
• By Natasha Barrow

NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.